Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold?
Amgen (AMGN) stock has risen 14% year-to-date, driven by recent FDA and European Commission approvals for its drug UPLIZNA. Despite strong revenue and EPS beats, the company missed significantly on free cash flow in Q4 2025. The article discusses analyst targets, market sentiment, and valuation models, suggesting potential upside if pipeline execution and margin recovery continue, with key catalysts including the Citi Oncology Leadership Summit and initiation of Maritide Phase 3 trials.